242 related articles for article (PubMed ID: 34954891)
1. EHMT1/EHMT2 in EMT, cancer stemness and drug resistance: emerging evidence and mechanisms.
Nachiyappan A; Gupta N; Taneja R
FEBS J; 2022 Mar; 289(5):1329-1351. PubMed ID: 34954891
[TBL] [Abstract][Full Text] [Related]
2. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
Watson ZL; Yamamoto TM; McMellen A; Kim H; Hughes CJ; Wheeler LJ; Post MD; Behbakht K; Bitler BG
Clin Epigenetics; 2019 Nov; 11(1):165. PubMed ID: 31775874
[TBL] [Abstract][Full Text] [Related]
3. G9a is essential for EMT-mediated metastasis and maintenance of cancer stem cell-like characters in head and neck squamous cell carcinoma.
Liu S; Ye D; Guo W; Yu W; He Y; Hu J; Wang Y; Zhang L; Liao Y; Song H; Zhong S; Xu D; Yin H; Sun B; Wang X; Liu J; Wu Y; Zhou BP; Zhang Z; Deng J
Oncotarget; 2015 Mar; 6(9):6887-901. PubMed ID: 25749385
[TBL] [Abstract][Full Text] [Related]
4. G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer.
Dong C; Wu Y; Yao J; Wang Y; Yu Y; Rychahou PG; Evers BM; Zhou BP
J Clin Invest; 2012 Apr; 122(4):1469-86. PubMed ID: 22406531
[TBL] [Abstract][Full Text] [Related]
5. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
Roy Burman D; Das S; Das C; Bhattacharya R
Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
[TBL] [Abstract][Full Text] [Related]
6. Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells.
Tao H; Li H; Su Y; Feng D; Wang X; Zhang C; Ma H; Hu Q
Mol Cell Biochem; 2014 Sep; 394(1-2):23-30. PubMed ID: 24833465
[TBL] [Abstract][Full Text] [Related]
7. Targeting EHMT2/ G9a for cancer therapy: Progress and perspective.
Jan S; Dar MI; Wani R; Sandey J; Mushtaq I; Lateef S; Syed SH
Eur J Pharmacol; 2021 Feb; 893():173827. PubMed ID: 33347828
[TBL] [Abstract][Full Text] [Related]
8. The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.
Suresh R; Ali S; Ahmad A; Philip PA; Sarkar FH
Adv Exp Med Biol; 2016; 890():57-74. PubMed ID: 26703799
[TBL] [Abstract][Full Text] [Related]
9. Histone Methyltransferases G9a/
Souza BK; Freire NH; Monteiro TS; Herlinger AL; Jaeger M; Dalmolin MGS; de Farias CB; Gregianin L; Brunetto AT; Brunetto AL; Thiele CJ; Roesler R
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894922
[TBL] [Abstract][Full Text] [Related]
10. Emerging Mechanisms by which EMT Programs Control Stemness.
Wilson MM; Weinberg RA; Lees JA; Guen VJ
Trends Cancer; 2020 Sep; 6(9):775-780. PubMed ID: 32312682
[TBL] [Abstract][Full Text] [Related]
11. G9a controls pluripotent-like identity and tumor-initiating function in human colorectal cancer.
Bergin CJ; Zouggar A; Haebe JR; Masibag AN; Desrochers FM; Reilley SY; Agrawal G; Benoit YD
Oncogene; 2021 Feb; 40(6):1191-1202. PubMed ID: 33323965
[TBL] [Abstract][Full Text] [Related]
12. MDC1 methylation mediated by lysine methyltransferases EHMT1 and EHMT2 regulates active ATM accumulation flanking DNA damage sites.
Watanabe S; Iimori M; Chan DV; Hara E; Kitao H; Maehara Y
Sci Rep; 2018 Jul; 8(1):10888. PubMed ID: 30022091
[TBL] [Abstract][Full Text] [Related]
13. De novo methylation of histone H3K23 by the methyltransferases EHMT1/GLP and EHMT2/G9a.
Vinson DA; Stephens KE; O'Meally RN; Bhat S; Dancy BCR; Cole RN; Yegnasubramanian S; Taverna SD
Epigenetics Chromatin; 2022 Nov; 15(1):36. PubMed ID: 36411491
[TBL] [Abstract][Full Text] [Related]
14. Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.
Lu Z; Tian Y; Salwen HR; Chlenski A; Godley LA; Raj JU; Yang Q
Anticancer Drugs; 2013 Jun; 24(5):484-93. PubMed ID: 23466651
[TBL] [Abstract][Full Text] [Related]
15. Demethylation of EHMT1/GLP Protein Reprograms Its Transcriptional Activity and Promotes Prostate Cancer Progression.
Besschetnova A; Han W; Liu M; Gao Y; Li M; Wang Z; Labaf M; Patalano S; Venkataramani K; Muriph RE; Macoska JA; Siegfried KR; Evans J; Balk SP; Gao S; Han D; Cai C
Cancer Res Commun; 2023 Aug; 3(8):1716-1730. PubMed ID: 37663929
[TBL] [Abstract][Full Text] [Related]
16. The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer.
Mayr C; Helm K; Jakab M; Ritter M; Shrestha R; Makaju R; Wagner A; Pichler M; Beyreis M; Staettner S; Jaeger T; Klieser E; Kiesslich T; Neureiter D
Hum Pathol; 2018 Feb; 72():117-126. PubMed ID: 29133140
[TBL] [Abstract][Full Text] [Related]
17. Methylation of DNA Ligase 1 by G9a/GLP Recruits UHRF1 to Replicating DNA and Regulates DNA Methylation.
Ferry L; Fournier A; Tsusaka T; Adelmant G; Shimazu T; Matano S; Kirsh O; Amouroux R; Dohmae N; Suzuki T; Filion GJ; Deng W; de Dieuleveult M; Fritsch L; Kudithipudi S; Jeltsch A; Leonhardt H; Hajkova P; Marto JA; Arita K; Shinkai Y; Defossez PA
Mol Cell; 2017 Aug; 67(4):550-565.e5. PubMed ID: 28803780
[TBL] [Abstract][Full Text] [Related]
18. Novel SAR for quinazoline inhibitors of EHMT1 and EHMT2.
Leenders R; Zijlmans R; van Bree B; van de Sande M; Trivarelli F; Damen E; Wegert A; Müller D; Ehlert JE; Feger D; Heidemann-Dinger C; Kubbutat M; Schächtele C; Lenstra DC; Mecinović J; Müller G
Bioorg Med Chem Lett; 2019 Sep; 29(17):2516-2524. PubMed ID: 31350126
[TBL] [Abstract][Full Text] [Related]
19. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
Du B; Shim JS
Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
[TBL] [Abstract][Full Text] [Related]
20. EHMT2 is a metastasis regulator in breast cancer.
Kim K; Son MY; Jung CR; Kim DS; Cho HS
Biochem Biophys Res Commun; 2018 Feb; 496(2):758-762. PubMed ID: 29337058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
